Dale A. Sander serves as the Chief Financial Officer, Chief Corporate Development Officer, and Treasurer at Humacyte, Inc., a biotechnology company focused on developing and commercializing human acellular vessels for various medical applications. With a robust background in finance and corporate development within the life sciences sector, Sander brings a wealth of experience and strategic insight to his roles at Humacyte. He joined the company in 2015 and has been instrumental in steering its financial strategy and growth initiatives. Prior to joining Humacyte, Sander held several senior finance and corporate development positions at notable biopharmaceutical companies. He was the Senior Vice President of Finance and Corporate Development at Talecris Biotherapeutics, where he played a key role in the company's successful initial public offering (IPO) and subsequent acquisition by Grifols. Before that, he served as Vice President of Corporate Development at MedImmune, which was acquired by AstraZeneca during his tenure. Sander's strategic acumen and financial expertise have been crucial in navigating complex transactions and fostering growth, making him a valuable asset to Humacyte. In his current roles at Humacyte, Sander is responsible for overseeing the company's financial operations, including budgeting, financial planning, and investor relations. Additionally, as Chief Corporate Development Officer, he leads efforts to identify and execute strategic partnerships and collaborations that enhance the company's portfolio and accelerate the development of its innovative therapies. Under his leadership, Humacyte has successfully raised significant capital through multiple financings, enabling the company to advance its clinical programs and move closer to bringing life-saving treatments to patients.